About MUVON

Therapeutics

MUVON Therapeutics is a Biotech Spin-off from the University of Zurich with the goal of developing and commercializing an autologous cell therapy for the regeneration of skeletal muscle tissue. Our initial area of focus is developing a safe and effective treatment for stress urinary incontinence in women, supporting them respectfully throughout their journey to a healthy life.

THE HISTORY

The research behind our technology began over 12 years ago in the laboratory of Tissue Engineering and Regenerative Medicine of the University of Zurich. Following the completion of preclinical Proof of Concept studies demonstrating the efficacy and safety of our therapy for the treatment of stress urinary incontinence in 2015, an international consortium led by the University of Zurich was established with the goal of transferring these results from the lab to the clinic. This project was given the acronym MUS.I.C. and is completely funded through a H2020 grant from the European Union. Having completed all necessary documentation and the GMP validation of the production process, the first in-human trial using our novel therapeutic approach began in January 2020 at the University Hospital of Zurich.

To ensure that this promising therapy and technology is developed further clinically as well as commercially and made available to the millions of patients in need, we decided to intensify our efforts and found a startup. Thus, MUVON Therapeutics was born. 

MEET THE TEAM

Steve Kappenthuler, PhD

CBO & Co-Founder

Steve joined the Team in 2019 during the last year of his PhD and since March 2020 is fully committed to the growth of MUVON.With his interdisciplinary background in science and economics... more

Natalie Hensky, MSc

GMP & R&D Technician

Natalie joined the MUS.I.C. project as a GMP production operator in October 2020 and is now a core member of the MUVON production team. Additionally, ... more

Nicolas Steinke, MSc

GMP & R&D Technician

Nicolas joined the team as a GMP Production operator in September 2019. He has since helped finalize the GMP-compliant process and is a core member of the production team. Furthermore, ... more

Beatrix Rauch,  MAS MTEC

Process Development Manager

​

Beatrix joined the Team in the beginning of 2021. With her broad work experience in many R&D labs internationally and her interdisciplinary background... more

BOARD OF DIRECTORS

Chris Jäggi

Chairman

Chris holds a Bachelor's degree of Science and a Master's degree in Business Administration. He supports the team with his extensive experience in the areas of strategy, market analytics, ... more

Jonathan Grahm

​

Jonathan studied Business Administration at the University of St. Gallen (HSG) and holds a Master’s degree in Marketing, Services & Communications Management. He is currently CMO ... more

Deana Mohr, PhD

Deana has been central to the development of MUVON from the very beginning. The results of her PhD thesis were the final step before the authorization of the muscle tissue-engineering... more

SCIENTIFIC ADVISORY BOARD

Prof. Stergios Doumouchtsis,

MD PhD

Prof. Stergios Doumouchtsis is currently a Consultant Obstetrician Gynaecologist and subspecialist Urogynaecologist in the Department of Obstetrics and Gynaecology, Epsom & St Helier University Hospitals NHS Trust... more

Florian Schmid, Dr. med.

Florian Schmid is currently working in the Department of Urology at the University Hospital Zurich. He completed his medical school education at the University of Zurich (UZH) in 2013... more

ADVISORS

STAY

INFORMED

Are you interested in investing or do you have questions about our therapy and technology?

Daniel Häring

Business/Financial Advisor

Daniel Häring has more than 20 years of experience in the field of multinational companies in various management positions. Daniel has led various strategic merger ... more